Imunon, Inc. - 8-K Filing
Imunon reported a Q1 2026 net loss of $4.3 million ($0.84 per share), up from $4.1 million ($3.15 per share) in the same period last year, driven by increased R&D expenses to $2.3 million and ongoing costs for its Phase 3 OVATION 3 trial. The company announced final data showing a median overall survival improvement of 14.7 months (45.1 vs. 30.4 months) in the IMNN-001 treatment arm compared to standard chemotherapy alone, with cash reserves at $4.8 million as of March 31. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $IMNN